BCTX BriaCell Therapeutics Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: BCTX

Price (delayed)

$2.26

Market cap

$36.12M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.8

Enterprise value

$29.87M

BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer.

Highlights
The EPS is up by 47% year-on-year and by 7% since the previous quarter
The net income has increased by 46% YoY and by 4.2% QoQ
BriaCell Therapeutics's quick ratio has plunged by 97% YoY and by 88% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.briacell.com

Key stats

What are the main financial stats of BCTX
Market
Shares outstanding
15.98M
Market cap
$36.12M
Enterprise value
$29.87M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$17.23M
EBITDA
-$17.21M
Free cash flow
-$31.26M
Per share
EPS
-$0.8
Free cash flow per share
-$1.96
Book value per share
-$0.51
Revenue per share
$0
TBVPS
$0.75
Balance sheet
Total assets
$12.23M
Total liabilities
$20.55M
Debt
$0
Equity
-$8.07M
Working capital
$7.82M
Liquidity
Debt to equity
0
Current ratio
2.99
Quick ratio
1.6
Net debt/EBITDA
0.36
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-57.7%
Return on equity
N/A
Return on invested capital
-731.9%
Return on capital employed
-207.4%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BCTX stock price

How has the BriaCell Therapeutics stock price performed over time
Intraday
0.89%
1 week
1.35%
1 month
-21.53%
1 year
-67.99%
YTD
-61.37%
QTD
-20.98%

Financial performance

How have BriaCell Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$31.72M
Net income
-$12.65M
Gross margin
N/A
Net margin
N/A
The company's operating income has shrunk by 65% YoY and by 20% QoQ
The net income has increased by 46% YoY and by 4.2% QoQ

Growth

What is BriaCell Therapeutics's growth rate over time

Valuation

What is BriaCell Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS is up by 47% year-on-year and by 7% since the previous quarter

Efficiency

How efficient is BriaCell Therapeutics business performance
BriaCell Therapeutics's ROIC has soared by 88% YoY but it has decreased by 13% from the previous quarter
BCTX's ROA is down by 20% since the previous quarter but it is up by 7% year-on-year

Dividends

What is BCTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BCTX.

Financial health

How did BriaCell Therapeutics financials performed over time
The total assets is 40% smaller than the total liabilities
BriaCell Therapeutics's quick ratio has plunged by 97% YoY and by 88% from the previous quarter
BriaCell Therapeutics's current ratio has shrunk by 94% YoY and by 83% QoQ
The debt is 100% greater than the equity

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.